Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Mirum Pharmaceuticals, Inc. Common Stock

MIRM

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Last trade $91.25
Day change -$0.33 (-0.36%)
Day range $89.20 – $95.88
Volume 152,578
Market cap $5.98B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$5.98B
Price / earnings
—
Price / book
-110.33×
Price / sales
8.91×
EV / sales
9.64×
EV / EBITDA
-7.44×

Profitability

Earnings per share
-$13.85
Return on assets
-88.04%
Return on equity
1,668.1%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-13.5×
Current ratio
2.07×
Quick ratio
1.98×
Cash ratio
0.86×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$273.85M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MIRM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$185.72M$176.24M$159.88M$148.93M$133.01M$127.79M$111.59M$99.41M
Cost of revenue$35.17M$30.35M$28.81M$28.26M$25.54M$23.42M$23.02M$22.78M
Gross profit$150.55M$145.9M$131.08M$120.67M$107.47M$104.36M$88.57M$76.63M
Selling, general and administrative$88.86M$81.47M$96.33M$74.13M$61.91M$63.29M$57.71M$56.83M
Research and development$121.43M$106.96M$824.21M$51.11M$42.96M$46.07M$46.04M$44.03M
Total operating expenses$210.3M$188.43M$920.54M$125.24M$104.87M$109.35M$103.75M$100.86M
Operating income-$59.75M-$42.54M-$789.47M-$4.57M$2.6M-$4.99M-$15.18M-$24.22M
Interest expense-$1.61M-$2.62M-$3.62M-$3.6M-$3.61M-$3.59M-$3.6M-$3.58M
Income before taxes-$40.23M-$65.54M-$789.68M-$4.96M$2.64M-$5.46M-$13.65M-$24.37M
Income taxes$538K$1.69M$475K$767K-$262K$402K$1.03M-$576K
Net income-$40.77M-$67.23M-$790.16M-$5.73M$2.91M-$5.86M-$14.68M-$23.79M
Net income attributable to common shareholders-$40.77M-$67.23M-$790.16M-$5.73M$2.91M-$5.86M-$14.68M-$23.79M
EBITDA-$52.86M-$35.6M-$782.59M$1.51M$8.67M$1.07M-$9.13M-$18.17M
Basic earnings per share-$0.62-$1.06-$13.43-$0.11$0.06-$0.12-$0.30-$0.49
Diluted earnings per share-$0.62-$1.06-$13.43-$0.13$0.05-$0.12-$0.30-$0.49

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV

Mirum Pharmaceuticals announced positive results from the Phase III AZURE-4 study for brelovitug, an investigational treatment for chronic hepatitis delta virus (HDV). The drug met its primary endpoint with 59% and 44% response rates across two dosing regimens versus 0% for delayed treatment. Combined with positive AZURE-1 data, these two studies will support a U.S. BLA filing in the first half of 2027, with potential commercial launch expected in Q4 2027.

Zacks Investment Research

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Mirum Pharmaceuticals (MIRM) is expected to report Q3 2026 earnings with a consensus loss of $0.53 per share but revenues up 32.7% year-over-year to $176.46 million. With a positive Earnings ESP of +56.93% and Zacks Rank #3, the company is positioned to likely beat consensus EPS estimates. The stock has beaten estimates twice in the last four quarters.

Zacks Investment Research

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

Mirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids. The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million.

Zacks Investment Research

Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV

Mirum Pharmaceuticals announced that brelovitug met the primary endpoint in the phase III AZURE-1 study for chronic hepatitis delta virus (HDV) treatment. 56% of patients on 300 mg weekly and 45% on 900 mg every four weeks achieved virologic response and ALT normalization compared to 0% in the delayed-treatment arm. The drug was well-tolerated with no new safety concerns. Phase III AZURE-4 data are expected in Q4 2026, with a potential BLA submission planned for H1 2027 and commercial launch expected in Q4 2027.

GlobeNewswire Inc.

Arcutis Expands Board of Directors with Appointment of Chris Peetz

Arcutis Biotherapeutics announced the appointment of Christopher Peetz, CEO of Mirum Pharmaceuticals, to its Board of Directors effective July 15, 2026. Peetz brings extensive biopharmaceutical leadership experience from roles at multiple companies including Onyx Pharmaceuticals and Tobira. The appointment comes as Arcutis continues to expand its ZORYVE (roflumilast) franchise for treating inflammatory skin diseases and evaluates pipeline expansion through strategic acquisitions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.